Heme Oxygenase 1‐Targeted Hybrid Nanoparticle for Chemo‐ and Immuno‐Combination Therapy in Acute Myelogenous Leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yong, Seok-Beom | - |
dc.contributor.author | Kim, Jaehyun | - |
dc.contributor.author | Chung, Jee Young | - |
dc.contributor.author | Ra, Sehee | - |
dc.contributor.author | Kim, Seong Su | - |
dc.contributor.author | Kim, Yong-Hee | - |
dc.date.accessioned | 2022-07-07T20:17:30Z | - |
dc.date.available | 2022-07-07T20:17:30Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/145369 | - |
dc.description.abstract | Acute myelogenous leukemia (AML) is a fatal blood cancer with high patient mortality. Daunorubicin and cytarabine are first-line chemotherapy for AML, with bone marrow transplantation in most cases. Recently, cancer immunotherapy has been challenged in AML and leukemia-niche myeloid cells are promising targets for the AML immunotherapy. Heme oxygenase 1 (HO1) is an antioxidative and cytoprotective enzyme inducing chemo-resistant AML and has been focused as an immune checkpoint molecule in tumor microenvironments. Herein, lipid-polymer hybrid nanoparticle (hNP) is loaded with tin mesoporphyrin (SnMP), a HO1-inhibitor, and non-covalently modified with an engineered antibody for leukemic cell-targeted delivery. HO1-inhibiting T-hNP (T-hNP/SnMP) enhances chemo-sensitivity in human leukemia cells. In a human AML-bearing orthotopic mouse model, intravenously injected T-hNP not only actively targets to human leukemia cells but passively targets to CD11b+ myeloid cells in a bone marrow niche. The T-hNP/SnMP enhances the chemo-therapeutic effect of daunorubicin and boosts immune response by reprogramming bone marrow myeloid cells resulting from the recruitment of the monocyte-lineage and induction of inflammatory genes. The ex vivo study demonstrates an enhanced immune response of HO1-inhibited bone marrow CD11b+ myeloid cells against apoptotic leukemia cells. Collectively, HO1-inhibiting dual cell-targeted T-hNP/SnMP has a strong potential as a novel therapeutic in AML. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Heme Oxygenase 1‐Targeted Hybrid Nanoparticle for Chemo‐ and Immuno‐Combination Therapy in Acute Myelogenous Leukemia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Hee | - |
dc.identifier.doi | 10.1002/advs.202000487 | - |
dc.identifier.scopusid | 2-s2.0-85085769862 | - |
dc.identifier.wosid | 000537255400001 | - |
dc.identifier.bibliographicCitation | ADVANCED SCIENCE, v.7, no.13, pp.1 - 14 | - |
dc.relation.isPartOf | ADVANCED SCIENCE | - |
dc.citation.title | ADVANCED SCIENCE | - |
dc.citation.volume | 7 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.subject.keywordPlus | TUMOR-ASSOCIATED MACROPHAGES | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | RNA | - |
dc.subject.keywordPlus | AML | - |
dc.subject.keywordAuthor | acute myelogenous leukemia | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordAuthor | heme oxygenase 1-targeted leukemia immunotherapy | - |
dc.subject.keywordAuthor | heme oxygenase 1-targeted nanomedicine | - |
dc.subject.keywordAuthor | immunotherapeutic nanomedicine | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/advs.202000487 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.